Immunomodulation effect of mesenchymal stem cells in islet transplantation

Shrestha, Manju; Nguyen, Tiep Tien; Park, Jooho; Choi, Jeong Uk; Yook, Simmyung; Jeong, Jee–Heon

doi:10.1016/j.biopha.2021.112042

Cited by 17 publications

(12 citation statements)

References 142 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is exemplified by the immunomodulatory effects of MSCs on T cells, B lymphocytes (B cells), dendritic cells (DCs), and NK cells, mainly via paracrine effects that involve the secretion of enzymes, chemokines, cytokines, anti-inflammatory mediators, growth factors, and extracellular vesicles [ 71 , 72 ]. Briefly, MSC activation is subjected to the stimulation of a multitude of inflammatory cytokines, including TNF- α and interferon- (IFN-) γ , which in turn shift to an immunosuppressive phenotype by inducing the secretion of soluble factors that mediated immunomodulatory activities, such as prostaglandin E2 (PGE2), hepatocyte growth factor (HGF), indoleamine-pyrrole 2,3-dioxygenase (IDO), and IL-10 [ 73 , 74 ]. Additionally, the paracrine immunomodulatory properties of MSCs are highly mediated by versatile signaling pathways like the telomerase-associated protein Rap1/NF- κ B pathway [ 75 ].…”

Section: The Mechanisms Of Msc Therapy In T2dmmentioning

confidence: 99%

Mesenchymal Stem Cells (MSCs): A Novel Therapy for Type 2 Diabetes

Gao

Zhang

Liang

et al. 2022

Stem Cells International

View full text Add to dashboard Cite

Although plenty of drugs are currently available for type 2 diabetes mellitus (T2DM), a subset of patients still failed to restore normoglycemia. Recent studies proved that symptoms of T2DM patients who are unresponsive to conventional medications could be relieved with mesenchymal stem/stromal cell (MSC) therapy. However, the lack of systematic summary and analysis for animal and clinical studies of T2DM has limited the establishment of standard guidelines in anti-T2DM MSC therapy. Besides, the therapeutic mechanisms of MSCs to combat T2DM have not been thoroughly understood. In this review, we present an overview of the current status of MSC therapy in treating T2DM for both animal studies and clinical studies. Potential mechanisms of MSC-based intervention on multiple pathological processes of T2DM, such as β-cell exhaustion, hepatic dysfunction, insulin resistance, and systemic inflammation, are also delineated. Moreover, we highlight the importance of understanding the pharmacokinetics (PK) of transplanted cells and discuss the hurdles in MSC-based T2DM therapy toward future clinical applications.

show abstract

Section: The Mechanisms Of Msc Therapy In T2dmmentioning

confidence: 99%

Mesenchymal Stem Cells (MSCs): A Novel Therapy for Type 2 Diabetes

Gao

Zhang

Liang

et al. 2022

Stem Cells International

View full text Add to dashboard Cite

show abstract

“…Recent studies in laboratory and animal models have shown that mesenchymal stem cells play an effective role in regulating immunity in autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and encephalitis [17,18]. Recently, many researchers have become interested in adult stem cells because they can transform into many tissues and there is no moral concern about using them [19,20]. Various studies have shown that insulinproducing cells can be made from stem cells isolated from bone marrow, fetal umbilical cord, fresh or frozen cord blood, and adipose tissue [21][22][23].…”

Section: Research Articlementioning

confidence: 99%

Insulin-producing cells from bone marrow stem cells versus injectable insulin for the treatment of rats with type I diabetes

Azeez

Jafar

Aziziaram³

et al. 2021

Cell. Mol. Biomed. Rep.

View full text Add to dashboard Cite

Recently, stem cells have been considered renewable cell sources in the treatment of diabetes and the development of insulin-producing cells. In this regard, the current study aimed to compare Insulin-producing cells from bone marrow stem cells with injectable insulin in rats with type I diabetes. For this purpose, 40 rats were divided into four groups: the control or healthy group, the diabetic control group, the group that received differentiated insulin-producing cells from bone marrow, and the group that received insulin treatment. To differentiate insulinproducing cells from bone marrow, the femoral bone marrow of rats was extracted using the flushing method. Differentiated cells were evaluated using dithizone-specific dye, anti-insulin-proinsulin antibodies, and antiinsulin beta receptors. Also, the expression of the pdx-I gene, as the specific gene of pancreatic cells, was examined by RT-PCR. The results showed that transplantation of insulin-producing cells could significantly increase blood insulin levels in diabetic rats. This increase intensified in the second stage of transplantation when more cells were injected into rats. Concerning decreasing blood sugar levels, differentiated cells were able to reduce blood sugar levels significantly. Even in the first stage of cell injection, in which the rats received a small number of cells, their blood sugar levels were controlled by these cells. As a result, the present study showed that repeated transplants of insulin-producing cells differentiated from bone marrow could decrease blood sugar and increase insulin levels. Article info

show abstract

“…There is evidence suggesting that CsA can affect the circulation and properties of bone-marrow-derived MSCs (BM-MSCs) [ 8 ] and promote the survival of MSCs in vivo; therefore, the combination of MSCs and CsA is a plausible alternative to improve treatment results [ 19 , 20 ]. All considered, it is still necessary to confirm the need of immunosuppressant drugs in combination with MSCs to increase the immunomodulating effect, which may have both positive and negative effects on the engraftment process [ 20 , 21 ].…”

Section: Discussionmentioning

confidence: 99%

An Effect of Cyclosporin A in a Treatment of Temporal Bone Defect Using hBM-MSCs

et al. 2022

View full text Add to dashboard Cite

Background. The treatment of middle ear cholesteatoma requires surgical treatment and the reconstruction of the temporal bone, which represents an ongoing problem. Otologists have focused on the research of materials allowing an airy middle ear and the preservation of hearing function to reconstruct the temporal bone. Methods. This study evaluated the effect of cyclosporin A (CsA) and a combined biomaterial in the healing process of postoperative temporal bone defects in an animal model. Cultured human Bone Marrow Mesenchymal Stromal Cells (hBM-MSCs) were mixed with hydroxyapatite (Cem-Ostetic®), and subsequently applied as a bone substitute after middle ear surgery, showing that the therapeutic potential of hBM-MSCs associated with bone regeneration and replacement is directly influenced by CsA, confirming that it promotes the survival of MSCs in vivo. Results. The therapeutic efficacy of the combination of MSCs with CsA is greater than the sole application of MSCs in a hydroxyapatite carrier. Conclusion. The reconstruction of a temporal bone defect using hBM-MSCs requires an immunosuppressant to improve the results of treatment.

show abstract

Immunomodulation effect of mesenchymal stem cells in islet transplantation

Cited by 17 publications

References 142 publications

Mesenchymal Stem Cells (MSCs): A Novel Therapy for Type 2 Diabetes

Mesenchymal Stem Cells (MSCs): A Novel Therapy for Type 2 Diabetes

Insulin-producing cells from bone marrow stem cells versus injectable insulin for the treatment of rats with type I diabetes

An Effect of Cyclosporin A in a Treatment of Temporal Bone Defect Using hBM-MSCs

Contact Info

Product

Resources

About